Oppenheimer Asset Management Inc. Sells 3,218 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Oppenheimer Asset Management Inc. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 31.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,950 shares of the medical research company’s stock after selling 3,218 shares during the period. Oppenheimer Asset Management Inc.’s holdings in IQVIA were worth $1,225,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. American National Bank & Trust acquired a new stake in IQVIA during the first quarter worth approximately $26,000. ST Germain D J Co. Inc. grew its holdings in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the fourth quarter valued at about $44,000. Finally, Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of several recent analyst reports. Robert W. Baird decreased their target price on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Mizuho decreased their price objective on shares of IQVIA from $210.00 to $190.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. JPMorgan Chase & Co. cut their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a research note on Monday, May 19th. Citigroup reiterated a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, HSBC downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $226.32.

IQVIA Trading Down 0.4%

NYSE IQV opened at $157.53 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a market capitalization of $27.25 billion, a PE ratio of 21.46, a price-to-earnings-growth ratio of 1.76 and a beta of 1.28. The business’s 50-day moving average price is $149.26 and its two-hundred day moving average price is $174.53.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the firm posted $2.54 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.